Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of sorafenib in treating
patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of
tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for
their growth.